News

  • 1 July 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has received U.S. Food & Drug Administration (FDA) approval under a premarket approval supplement for 3T full-body magnetic resonance imaging (MRI) conditional labeling for the Axonics r-SNM System®.

  • 30 June 2020

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced the initiation of a Phase 1 clinical study with high-dose setanaxib in healthy subjects.

  • 18 June 2020

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced the presentation of additional data from the Phase 2 trial of setanaxib in primary biliary cholangitis (PBC).

  • 16 June 2020

    Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the results of MOSAIC, the North American feasibility study of the alfapump in recurrent and refractory liver ascites, have been published in Liver Transplantation, the peer-reviewed publication of the American Association for the Study of Liver Diseases.

  • 12 June 2020

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today presented positive biomarker, efficacy, and safety data from its ongoing Phase 2 open-label extension trial of its lead candidate, mavorixafor, in patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. The results included significant reductions in yearly infection rates and wart burden in WHIM patients treated for at least six months with mavorixafor. The data were presented in an e-poster at the 25th European Hematology Association (EHA) Annual Congress, taking place virtually from June 11-14, 2020.